Compare MYGN & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | ASPI |
|---|---|---|
| Founded | 1991 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 496.7M |
| IPO Year | 1996 | 2022 |
| Metric | MYGN | ASPI |
|---|---|---|
| Price | $5.67 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $7.64 | ★ $12.00 |
| AVG Volume (30 Days) | 1.3M | ★ 4.4M |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | $23,849,000.00 |
| Revenue This Year | $6.86 | $68.41 |
| Revenue Next Year | $5.45 | $126.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.33 | ★ 475.48 |
| 52 Week Low | $3.53 | $3.61 |
| 52 Week High | $8.59 | $14.49 |
| Indicator | MYGN | ASPI |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 31.21 |
| Support Level | $5.57 | $3.86 |
| Resistance Level | $6.34 | $5.88 |
| Average True Range (ATR) | 0.29 | 0.34 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 3.51 | 14.36 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.